Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter

Clinical and Experimental Immunology

Volumn 120, Issue 2, 2000, Pages 317-323

  Calzado, M A ^a   Macho, A ^a   Lucena, C ^a   Muñoz, Eduardo ^a  

^a Universidad de Cordoba   (Spain)

Author keywords

HIV 1; Hydroxyurea; LTR; NF B

Indexed keywords

CD69 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL CYCLE; CELL LINE, TRANSFORMED; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HIV ENHANCER; HUMANS; HYDROXYUREA; JURKAT CELLS; NF-KAPPA B; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; RIBONUCLEOTIDE REDUCTASES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC;

EID: 0034125405     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01203.x     Document Type: Article

References (58)

1. 1 Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, Gallo RC. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986; 231:850-3.
2. 2 Folks T, Kelly J, Benn S et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol 1986; 136:4049-53.
3. 3 Fauci AS, Schnittman SM, Poli G. Koenig S, Pantaleo G. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114:678-93.
4. 4 Rosenberg ZF, Fauci AS. Induction of expression of HIV in latently or chronically infected cells. AIDS Res Hum Retrovir 1989; 5:1-4.
5. 5 Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990; 87:782-5.
6. 6 Monté D, Groux H, Raharinivo B et al. Productive human immunodeficiency virus-I infection of megakaryocytic cells is enhanced by tumor necrosis factor-alpha. Blood 1992; 79:2670-9.
7. 7 Clouse KA, Powell D, Washington I et al. Monokine regulation of human immunodeficiency virus-I expression in a chronically infected human T cell clone. J Immunol 1989; 142:431-8.
8. 8 Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retrovir 1992; 8:191-7.
9. 9 Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 1992; 6:347-63.
10. 10 Cullen BR. Regulation of human immunodeficiency virus replication. Annu Rev Mierobiol 1991; 45:219-50.
11. 11 Lin R, Gewert D, Hiscott J. Differential transcriptional activation in vitro by NF-kappa B/Rel proteins. J Biol Chem 1995; 270:3123-31.
12. 12 Garcia JA, Gaynor RB. The human immunodeficiency virus type-1 long terminal repeat and its role in gene expression. Prog Nucl Acid Res Mol Biol 1994; 49:157-96.
13. 13 Jones KA, Peterlin BM. Control of RNA initiation and elongation at the HIV-I promoter. Annu Rev Biochem 1994; 63:717-43.
14. 14 Grilli M, Chiu JJ, Lenardo MJ. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993; 143:1-62.
15. 15 Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995; 80:529-32.
16. 16 Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 9:2723-35.
17. 17 Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87:13-20.
18. 18 Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characteri/ation of an IkappaB kinase. Cell 1997; 90:373-83.
19. 19 Mercurio F, Zhu H, Murray BW et al. IKK-1 and IKK-2: cytokine-activated rkappaB kinases essential for NF-kappaB activation. Science 1997; 278:860-6.
20. 20 Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997; 278:866-9.
21. 21 Richman DD. Resistance, drug failure, and disease progression. AIDS Res Hum Retrovir 1994; 10:901-5.
22. 22 Hammer SM, Kessler HA, Saag MS. Issues in combination antiretroviral therapy: a review. J Acquir Immune Defic Syndr 1994; 7:S24-37.
23. 23 Montaner JS, Hogg RS, O'Shaughnessy MV. Emerging international consensus for use of antiretroviral therapy. Lancet 1997; 349:1042.
24. 24 Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993; 90:8925-8.
25. 25 Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19:11-19.
26. 26 Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-5.
27. 27 Alter BP, Gilbert HS. The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes. Blood 1985; 66:373-9.
28. 28 Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132-6.
29. 29 Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90:3370-7.
30. 30 Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol 1997; 98:838-44.
31. 31 Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Mullicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317-22.
32. 32 Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet 1994; 343:1292.
33. 33 Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994; 46:767-72.
34. 34 Meyerhans A, Vartanian JP, Hultgren C, Plikat U, Karlsson A, Wang L, Eriksson S, Wain-Hobson S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994; 68:535-40.
35. 35 Israël N, Gougerot-Pocidalo MA, Aillet F, Virilizier JL. Redox status of cells influences constitutive or induced NF-kappa B translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol 1992; 149:3386-93.
36. 36 López-Cabrera M, Muñoz E, Blázquez MV, Ursa MA, Santis AG, Sánchez-Madrid F. Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-alpha-responsive elements. J Biol Chem 1995; 270:21545-51.
37. 37 Macho A, Blázquez MV, Navas P, Muñoz E. Induction of apoptosis by vanilloid compounds does not require de novo gene transcription and activator protein 1 activity. Cell Growth Differ 1998; 9:277-86.
38. 38 Cebrián M, Yagüe E, Rincón M, López-Botet M, Landázuri MO, Sánchez-Madrid F. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J Exp Med 1988; 168:1621-37.
39. 39 Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
40. 40 Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30.
41. 41 Wise DA, Brinkley BR. Mitosis in cells with unreplicated genomes (MUGs): cell cycle arrest G1/S. Cell Motil Cytoskeleton 1997; 36:291-302.
42. 42 Belt RJ, Haas CD, Kennedy J, Taylor S. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 1980; 46:455-62.
43. 43 Romanelli F, Pomeroy C, Smith KM. Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Pharmacotherapy 1999; 19: 196-204.
44. 44 Rutschmann OT, Opravil M, Iten A et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998; 12:F71-77.
45. 45 Cohen J. HIV supressed long after treatment. Science 1997; 227:1927.
46. 46 Vila J, Nugier F, Barguès G, Vallet T, Peyramond D, Hamedi-Sangsari F, Seigneurin JM. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997; 350:635-6.
47. 47 Back NKT, Berkhout B. Deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Anti-microbial Agents Chemother 1997; 41:2484-91.
48. 48 Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996; 7:93-124.
49. 49 Molina JM, Scadden DT, Byrn R, Dinarello CA, Groopman JE. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989; 84:733-7.
50. 50 Lähdevirta J, Maury CPJ, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988; 85:289-91.
51. 51 Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90:5974-8.
52. 52 Odeh M. The role of tumour necrosis factor-alpha in acquired immunodeficiency syndrome. J Intern Med 1990; 228:549-56.
53. 53 Tamami M, Lindholm PF, Brady JN. The retinoblastoma gene product (Rb) induces binding of a conformationally inactive nuclear factor-kappaB. J Biol Chem 1996; 271:24551-6.
54. 54 Kundu M, Guermah M, Roeder RG, Amini S, Khalili K. Interaction between cell cycle regulator, E2F-1, and NF-kappaB mediates repression of HIV-1 gene transcription. J Biol Chem 1997; 272:29468-74.
55. 55 Kundu M, Srinivasan A, Pomerantz RJ, Khalili K. Evidence that a cell cycle regulator, E2F1, down-regulates transcriptional activity of the human immunodeficiency virus type 1 promoter. J Virol 1995; 69:6940-6.
56. 56 Sawaya BE, Khalili K, Mercer WE, Denisova L, Amini S. Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription. J Biol Chem 1998; 273:20052-7.
57. 57 Gualberto A, Hixon ML, Finco TS, Perkins ND, Nabel GJ, Baldwin As Jr. A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol Cell Biol 1995; 15:3450-9.
58. 58 Gummuluru S, Emerman M. Cell cycle-mediated and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed cell lines. J Virol 1999; 73:5422-30.